Literature DB >> 2153487

Acetylation of 5-aminosalicylic acid by isolated human colonic epithelial cells.

A Ireland1, J D Priddle, D P Jewell.   

Abstract

1. This study investigates the acetylation of 5-aminosalicylic acid by isolated human colonic epithelial cells. 2. After incubation of intact cells with 0.1 mmol/l 5-aminosalicylic acid, N-acetyl-5-aminosalicylic acid was detected in a concentration of 141 (+/- 23.8 SEM) nmol/g dry weight in the incubation medium, and 34.8 (+/- 5.5 SEM) nmol/g dry weight intracellularly. No unchanged 5-aminosalicylic acid was detected inside the cell. 3. Acetylation of 5-aminosalicylic acid by a cell homogenate was very poor, but the addition of 1 mmol/l acetyl-CoA resulted in complete conversion of 0.1 mmol/l 5-aminosalicylic acid to N-acetyl-5-aminosalicylic acid. 4. N-Acetyltransferase activity was detected in the cytosol, with a mean of 3.3 nmol min-1 mg-1 of protein. There was no N-acetyltransferase activity in the brush border. There was no difference in enzyme activity between epithelial cells derived from normal, Crohn's disease or ulcerative colitis patients. 5. Preliminary characterization of the N-acetyltransferase enzyme suggests a molecular weight of 150,000.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153487     DOI: 10.1042/cs0780105

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  15 in total

Review 1.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

Review 2.  Sulphasalazine in ulcerative colitis: in memoriam?

Authors:  J Hayllar; I Bjarnason
Journal:  Gut       Date:  1991-05       Impact factor: 23.059

Review 3.  Human colonocyte detoxification.

Authors:  W E Roediger; W Babidge
Journal:  Gut       Date:  1997-12       Impact factor: 23.059

Review 4.  Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.

Authors:  S B Hanauer; G Stathopoulos
Journal:  Drug Saf       Date:  1991 May-Jun       Impact factor: 5.606

5.  Sulphasalazine induced renal failure.

Authors:  A D Dwarakanath; J Michael; R N Allan
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

6.  Mesalazine pharmacokinetics and NAT2 phenotype.

Authors:  Hendrik Lück; Martina Kinzig; Alexander Jetter; Uwe Fuhr; Fritz Sörgel
Journal:  Eur J Clin Pharmacol       Date:  2008-08-14       Impact factor: 2.953

7.  Acute murine colitis reduces colonic 5-aminosalicylic acid metabolism by regulation of N-acetyltransferase-2.

Authors:  Verónica Ramírez-Alcántara; Marshall H Montrose
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-17       Impact factor: 4.052

8.  What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?

Authors:  S A Riley
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

9.  Superoxide inhibition following different stimuli of respiratory burst and metabolism of aminosalicylates in neutrophils.

Authors:  H Allgayer; S Rang; U Klotz; P Böhne; J Retey; W Kruis; R Gugler
Journal:  Dig Dis Sci       Date:  1994-01       Impact factor: 3.199

10.  Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine.

Authors:  Daniel B Zandman; Mark A Peppercorn
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.